FCM
SAGE
Farallon Capital Management’s Sage Therapeutics SAGE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $390K | Hold |
42,800
| – | – | ﹤0.01% | 93 |
|
|
2025
Q1 | $340K | Hold |
42,800
| – | – | ﹤0.01% | 98 |
|
|
2024
Q4 | $232K | Hold |
42,800
| – | – | ﹤0.01% | 113 |
|
|
2024
Q3 | $309K | Hold |
42,800
| – | – | ﹤0.01% | 115 |
|
|
2024
Q2 | $465K | Hold |
42,800
| – | – | ﹤0.01% | 105 |
|
|
2024
Q1 | $802K | Hold |
42,800
| – | – | ﹤0.01% | 119 |
|
|
2023
Q4 | $927K | Hold |
42,800
| – | – | ﹤0.01% | 106 |
|
|
2023
Q3 | $881K | Buy |
+42,800
| New | +$881K | ﹤0.01% | 111 |
|
|
2021
Q2 | – | Sell |
-345,000
| Closed | -$25.8M | – | 308 |
|
|
2021
Q1 | $25.8M | Sell |
345,000
-705,000
| -67% | -$52.8M | 0.13% | 93 |
|
|
2020
Q4 | $90.8M | Hold |
1,050,000
| – | – | 0.55% | 47 |
|
|
2020
Q3 | $64.2M | Buy |
1,050,000
+200,000
| +24% | +$12.2M | 0.44% | 56 |
|
|
2020
Q2 | $35.3M | Buy |
850,000
+175,000
| +26% | +$7.28M | 0.28% | 67 |
|
|
2020
Q1 | $19.4M | Buy |
675,000
+175,000
| +35% | +$5.03M | 0.17% | 68 |
|
|
2019
Q4 | $36.1M | Buy |
500,000
+127,200
| +34% | +$9.18M | 0.24% | 62 |
|
|
2019
Q3 | $52.3M | Sell |
372,800
-127,200
| -25% | -$17.8M | 0.4% | 48 |
|
|
2019
Q2 | $91.5M | Sell |
500,000
-100,000
| -17% | -$18.3M | 0.6% | 38 |
|
|
2019
Q1 | $95.4M | Buy |
600,000
+200,000
| +50% | +$31.8M | 0.72% | 37 |
|
|
2018
Q4 | $38.3M | Sell |
400,000
-225,000
| -36% | -$21.6M | 0.28% | 51 |
|
|
2018
Q3 | $88.3M | Hold |
625,000
| – | – | 0.52% | 36 |
|
|
2018
Q2 | $97.8M | Buy |
625,000
+180,000
| +40% | +$28.2M | 0.6% | 36 |
|
|
2018
Q1 | $71.7M | Buy |
445,000
+45,000
| +11% | +$7.25M | 0.5% | 40 |
|
|
2017
Q4 | $65.9M | Buy |
400,000
+156,500
| +64% | +$25.8M | 0.54% | 36 |
|
|
2017
Q3 | $15.2M | Buy |
243,500
+143,500
| +144% | +$8.94M | 0.13% | 61 |
|
|
2017
Q2 | $7.96M | Buy |
+100,000
| New | +$7.96M | 0.08% | 69 |
|